MA54458B1 - Formes cristallines et formes salines d'un inhibiteur de kinase - Google Patents
Formes cristallines et formes salines d'un inhibiteur de kinaseInfo
- Publication number
- MA54458B1 MA54458B1 MA54458A MA54458A MA54458B1 MA 54458 B1 MA54458 B1 MA 54458B1 MA 54458 A MA54458 A MA 54458A MA 54458 A MA54458 A MA 54458A MA 54458 B1 MA54458 B1 MA 54458B1
- Authority
- MA
- Morocco
- Prior art keywords
- crystalline
- relates
- compound
- kinase inhibitor
- salt forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des formes cristallines de la base libre de l'inhibiteur de c-Met, Composé 1. L'invention concerne également des formes cristallines de sels du Composé 1. L'invention concerne également des compositions pharmaceutiques comprenant les polymorphes solides de la base libre et des sels du Composé 1. L'invention concerne en outre des méthodes de traitement d'une maladie, d'un trouble ou d'un syndrome médié au moins en partie par la modulation de l'activité in vivo d'une protéine kinase.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779430P | 2018-12-13 | 2018-12-13 | |
| US201962856469P | 2019-06-03 | 2019-06-03 | |
| EP19836338.4A EP3894012B1 (fr) | 2018-12-13 | 2019-12-12 | Formes cristallines et formes salines d'un inhibiteur de kinase |
| PCT/US2019/065972 WO2020123800A1 (fr) | 2018-12-13 | 2019-12-12 | Formes cristallines et formes salines d'un inhibiteur de kinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA54458A MA54458A (fr) | 2021-10-20 |
| MA54458B1 true MA54458B1 (fr) | 2025-09-30 |
Family
ID=69160358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA54458A MA54458B1 (fr) | 2018-12-13 | 2019-12-12 | Formes cristallines et formes salines d'un inhibiteur de kinase |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US12017995B2 (fr) |
| EP (2) | EP3894012B1 (fr) |
| JP (3) | JP7509779B2 (fr) |
| KR (2) | KR102828472B1 (fr) |
| CN (1) | CN113329790A (fr) |
| AU (2) | AU2019395419B2 (fr) |
| BR (1) | BR112021011333A2 (fr) |
| CA (1) | CA3122840A1 (fr) |
| CL (1) | CL2021001537A1 (fr) |
| CO (1) | CO2021007613A2 (fr) |
| CR (1) | CR20210375A (fr) |
| DK (1) | DK3894012T3 (fr) |
| ES (1) | ES3052838T3 (fr) |
| FI (1) | FI3894012T3 (fr) |
| GE (1) | GEP20247596B (fr) |
| HR (1) | HRP20251122T1 (fr) |
| HU (1) | HUE072868T2 (fr) |
| IL (2) | IL283860B2 (fr) |
| LT (1) | LT3894012T (fr) |
| MA (1) | MA54458B1 (fr) |
| MD (1) | MD3894012T2 (fr) |
| MX (1) | MX2021006951A (fr) |
| PE (1) | PE20211757A1 (fr) |
| PH (1) | PH12021551356A1 (fr) |
| PL (1) | PL3894012T4 (fr) |
| PT (1) | PT3894012T (fr) |
| RS (1) | RS67216B1 (fr) |
| SG (1) | SG11202105949RA (fr) |
| SI (1) | SI3894012T1 (fr) |
| SM (1) | SMT202500346T1 (fr) |
| TW (1) | TWI852963B (fr) |
| WO (1) | WO2020123800A1 (fr) |
| ZA (1) | ZA202103844B (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA128476C2 (uk) * | 2018-01-26 | 2024-07-24 | Екселіксіс, Інк. | Сполуки для лікування кіназозалежних розладів |
| CA3139148A1 (fr) * | 2019-06-03 | 2020-12-10 | Exelixis, Inc. | Formes de sel cristallin d'un inhibiteur de kinase |
| TWI887405B (zh) | 2020-04-30 | 2025-06-21 | 美商艾克塞里克斯公司 | 製備激酶抑制劑之方法 |
| EP4188376A1 (fr) * | 2020-07-31 | 2023-06-07 | Exelixis, Inc. | Associations pour le traitement du cancer |
| CR20230223A (es) * | 2020-11-05 | 2023-07-07 | Exelixis Inc | Composiciones farmacéuticas de un inhibidor de cinasa |
| CN112650176B (zh) * | 2020-12-22 | 2022-08-30 | 天能化工有限公司 | 一种盐酸解析开停车工序的dcs控制方法 |
| TW202334090A (zh) * | 2021-11-03 | 2023-09-01 | 美商艾克塞里克斯公司 | 用於治療激酶依賴性病症之化合物 |
| TW202340148A (zh) | 2021-12-22 | 2023-10-16 | 美商艾克塞里克斯公司 | 激酶抑制劑之結晶形式及鹽形式 |
| CN116751161A (zh) * | 2023-06-28 | 2023-09-15 | 中国人民解放军军事科学院军事医学研究院 | 喹啉类化合物及其制备方法、药物组合物及医药用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2213661E (pt) | 2003-09-26 | 2011-12-15 | Exelixis Inc | Moduladores de c-met e métodos de uso |
| WO2006113546A2 (fr) | 2005-04-15 | 2006-10-26 | Neogenix Oncology, Inc. | Anticorps monoclonaux recombines et antigenes correspondants contre les cancers du colon et du pancreas |
| EP2340244A4 (fr) | 2008-10-14 | 2012-07-25 | Ning Xi | Composés et procédés d'utilisation |
| SG173014A1 (en) | 2009-01-16 | 2011-08-29 | Exelixis Inc | Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
| CN102408411B (zh) | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| CA2886433C (fr) | 2012-10-04 | 2022-01-04 | Dana-Farber Cancer Institute, Inc. | Anticorps monoclonaux humains anti pd-l1 et procedes d'utilisation |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| KR102354963B1 (ko) | 2014-02-14 | 2022-01-21 | 엑셀리시스, 인코포레이티드 | N-｛4-[(6,7-다이메톡시퀴놀린-4-일)옥시]페닐｝-n'-(4-플루오로페닐) 사이클로프로판-1,1-다이카복스아마이드의 결정질 고체 형태, 제조 방법 및 사용 방법 |
| CN104817497B (zh) | 2015-03-20 | 2017-03-08 | 南京众睿缘生物科技有限公司 | 一种炔代喹啉衍生物及其制备方法和用途 |
| AU2018272088C1 (en) | 2017-05-26 | 2022-09-22 | Exelixis, Inc. | Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-N'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
| UA128476C2 (uk) | 2018-01-26 | 2024-07-24 | Екселіксіс, Інк. | Сполуки для лікування кіназозалежних розладів |
| CA3139148A1 (fr) * | 2019-06-03 | 2020-12-10 | Exelixis, Inc. | Formes de sel cristallin d'un inhibiteur de kinase |
-
2019
- 2019-12-12 PL PL19836338.4T patent/PL3894012T4/pl unknown
- 2019-12-12 HR HRP20251122TT patent/HRP20251122T1/hr unknown
- 2019-12-12 MD MDE20211022T patent/MD3894012T2/ro unknown
- 2019-12-12 PE PE2021000862A patent/PE20211757A1/es unknown
- 2019-12-12 SM SM20250346T patent/SMT202500346T1/it unknown
- 2019-12-12 EP EP19836338.4A patent/EP3894012B1/fr active Active
- 2019-12-12 DK DK19836338.4T patent/DK3894012T3/da active
- 2019-12-12 IL IL283860A patent/IL283860B2/en unknown
- 2019-12-12 FI FIEP19836338.4T patent/FI3894012T3/fi active
- 2019-12-12 RS RS20250909A patent/RS67216B1/sr unknown
- 2019-12-12 LT LTEPPCT/US2019/065972T patent/LT3894012T/lt unknown
- 2019-12-12 MA MA54458A patent/MA54458B1/fr unknown
- 2019-12-12 PT PT198363384T patent/PT3894012T/pt unknown
- 2019-12-12 ES ES19836338T patent/ES3052838T3/es active Active
- 2019-12-12 CR CR20210375A patent/CR20210375A/es unknown
- 2019-12-12 GE GEAP201915695A patent/GEP20247596B/en unknown
- 2019-12-12 KR KR1020217021734A patent/KR102828472B1/ko active Active
- 2019-12-12 KR KR1020257021669A patent/KR20250103803A/ko active Pending
- 2019-12-12 WO PCT/US2019/065972 patent/WO2020123800A1/fr not_active Ceased
- 2019-12-12 CN CN201980090041.5A patent/CN113329790A/zh active Pending
- 2019-12-12 IL IL320433A patent/IL320433A/en unknown
- 2019-12-12 MX MX2021006951A patent/MX2021006951A/es unknown
- 2019-12-12 CA CA3122840A patent/CA3122840A1/fr active Pending
- 2019-12-12 HU HUE19836338A patent/HUE072868T2/hu unknown
- 2019-12-12 AU AU2019395419A patent/AU2019395419B2/en active Active
- 2019-12-12 EP EP25183289.5A patent/EP4631505A3/fr active Pending
- 2019-12-12 JP JP2021533537A patent/JP7509779B2/ja active Active
- 2019-12-12 BR BR112021011333-9A patent/BR112021011333A2/pt unknown
- 2019-12-12 US US17/312,658 patent/US12017995B2/en active Active
- 2019-12-12 SG SG11202105949RA patent/SG11202105949RA/en unknown
- 2019-12-12 SI SI201930963T patent/SI3894012T1/sl unknown
- 2019-12-13 TW TW108145868A patent/TWI852963B/zh active
-
2021
- 2021-06-04 ZA ZA2021/03844A patent/ZA202103844B/en unknown
- 2021-06-09 PH PH12021551356A patent/PH12021551356A1/en unknown
- 2021-06-10 CO CONC2021/0007613A patent/CO2021007613A2/es unknown
- 2021-06-11 CL CL2021001537A patent/CL2021001537A1/es unknown
-
2023
- 2023-12-27 JP JP2023221085A patent/JP7783870B2/ja active Active
-
2024
- 2024-05-07 US US18/657,052 patent/US20240300897A1/en active Pending
-
2025
- 2025-09-22 AU AU2025234277A patent/AU2025234277A1/en active Pending
- 2025-11-28 JP JP2025208367A patent/JP2026031599A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54458B1 (fr) | Formes cristallines et formes salines d'un inhibiteur de kinase | |
| MX2023007192A (es) | Inhibidores de prmt5. | |
| EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
| EA200301232A1 (ru) | Новые соединения арилсульфонамида и их применение для лечения ожирения, диабета типа ii и нарушений центральной нервной системы | |
| MA51627B1 (fr) | Benzofurane, benzopyrrole, benzothiophène substitués et inhibiteurs du complément structurellement apparentés | |
| MA43979B1 (fr) | Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques | |
| NO20061074L (no) | Forbindelser og sammensetninger som inbibitorer av reseptortyrosinkinaseaktivitet | |
| ATE318267T1 (de) | Einige alkylendiamin-substituierte heterocyclen | |
| EA200300528A1 (ru) | 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6 | |
| ZA202108034B (en) | Crystalline salt forms of a kinase inhibitor | |
| BRPI0606690A2 (pt) | composto; uso do composto para o tratamento de uma doença ou distúrbio associado com uma atividade excessiva de bace; e composição farmacêutica | |
| CY1107274T1 (el) | Παραγωγα αλφα-αμινοαμιδιου χρησιμα σαν παραγοντες κατα της ημικρανιας | |
| GEAP202516634A (en) | Heteroaryl compounds for the treatment of pain | |
| AR051965A1 (es) | Sales de la n-[2-( { (3r)-1-[trans-4-hidroxi-4-(6- metoxipiridin-3-il)-ciclohexil] pirrolidin-3- il} amino)-2- oxoetil]-3-(trifluormetil) benzamida | |
| FR3056909B1 (fr) | Composition comprenant au moins un sel pharmaceutiquement acceptable d'elafibranor soluble en milieux aqueux presentant une absorption intestinale amelioree | |
| DE602006013191D1 (de) | Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren | |
| JOP20220228A1 (ar) | مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة | |
| ATE461697T1 (de) | Phospholipidderivate von valproinsäure und ihre kombinationen | |
| EP3620457A4 (fr) | Composé dérivé de pyrimidine, isomère optique, ou sel pharmaceutiquement acceptable de celui-ci, et composition pour prévenir ou traiter une maladie liée au tyro 3 le comprenant en tant que principe actif | |
| BR112022015925A2 (pt) | Combinações de compostos beta-lactâmicos, probenecida e ácido valproico e usos dos mesmos | |
| CL2023001268A1 (es) | Composiciones farmacéuticas de un inhibidor de cinasa | |
| MA68743B1 (fr) | Composés et compositions pour le traitement d'états associés à l'activité du récepteur de lpa | |
| JOP20220082A1 (ar) | مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 | |
| EA200500045A1 (ru) | Новые соединения, их применение и получение | |
| EA202191151A1 (ru) | Новые аминофосфиновые производные в качестве ингибиторов аминопептидазы а |